Cetera Investment Advisers
NBIX icon

Cetera Investment Advisers’s Neurocrine Biosciences NBIX Stock Holding History

Cetera Investment Advisers’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.67M Buy
20,245
+6,756
+50% +$896K ﹤0.01% 2015
2025
Q4 		$1.91M Buy
13,489
+368
+3% +$53.3K ﹤0.01% 2246
2025
Q3 		$1.84M Buy
13,121
+4,061
+45% +$550K ﹤0.01% 2245
2025
Q2 		$1.14M Sell
9,060
-2,797
-24% -$321K ﹤0.01% 2259
2025
Q1 		$1.31M Buy
11,857
+3,688
+45% +$467K ﹤0.01% 2052
2024
Q4 		$1.12M Buy
8,169
+2,593
+47% +$321K ﹤0.01% 2092
2024
Q3 		$642K Sell
5,576
-1,536
-22% -$211K ﹤0.01% 2450
2024
Q2 		$979K Buy
7,112
+519
+8% +$71.2K ﹤0.01% 2090
2024
Q1 		$909K Buy
+6,593
New +$900K ﹤0.01% 2152
2023
Q2 		– Sell
-2,592
Closed -$262K – 2267
2023
Q1 		$262K Buy
2,592
+610
+31% +$63.5K ﹤0.01% 1782
2022
Q4 		$237K Buy
+1,982
New +$232K ﹤0.01% 1803

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Cetera Investment Advisers's NBIX Position: Q1 2026 in Review

Cetera Investment Advisers increased its Neurocrine Biosciences (NBIX) stake by 50% in Q1 2026, buying an estimated $896K and bringing the position to 20,245 shares worth $2.67M. The position accounts for ﹤0.01% of the portfolio, ranked #2015.

Cetera Investment Advisers first reported a position in NBIX in Q4 2022 and has held it in 11 quarters since. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • Cetera Investment Advisers held 20,245 shares of Neurocrine Biosciences worth $2.67M as of Q1 2026.
  • Cetera Investment Advisers bought 6,756 Neurocrine Biosciences shares in Q1 2026, an estimated $896K.
  • Neurocrine Biosciences made up ﹤0.01% of Cetera Investment Advisers's portfolio in Q1 2026, its #2015 holding.
  • Cetera Investment Advisers first reported a position in Neurocrine Biosciences in Q4 2022 and has held it in 11 quarters since.
  • 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Cetera Investment Advisers's 13F filing for Q1 2026, filed 13 May 2026.